Related Experiment Video

Updated: Jun 10, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh

Joel W Neal1, Lecia V Sequist

  • 1Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA, jwneal@stanford.edu

Current Treatment Options in Oncology
|August 3, 2010
PubMed

Insights

Targeted therapies like crizotinib offer new hope for non-small cell lung cancer (NSCLC) with ALK translocations. Other agents show mixed results, requiring cautious development for lung cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Anaplastic lymphoma kinase (ALK) inhibitors represent a significant advancement in treating non-small cell lung cancer (NSCLC) with specific genetic alterations.
  • The development of targeted therapies for NSCLC is rapidly evolving, with several drug classes under investigation.

Purpose of the Study:

  • To review the current landscape and clinical development of novel targeted agents for NSCLC.
  • To assess the efficacy and safety of agents targeting ALK, IGF-1R, HDAC, and hedgehog signaling pathways in NSCLC.

Main Methods:

  • Review of recent clinical trial data and published literature on targeted therapies in NSCLC.
  • Analysis of therapeutic strategies including ALK inhibitors, monoclonal antibodies, HDAC inhibitors, and pathway inhibitors.

Main Results:

  • Crizotinib shows promise as a key treatment for ALK-positive NSCLC.
  • Figitumumab combined with chemotherapy demonstrated increased toxicity and mortality in squamous NSCLC.
  • Vorinostat (HDAC inhibitor) did not improve overall survival in a large trial, suggesting a need for more selective agents.
  • Hedgehog (Hh) signaling pathway inhibitors show early promise in both NSCLC and small cell lung cancer (SCLC).

Conclusions:

  • Targeted therapies, particularly ALK inhibitors, are becoming integral to NSCLC treatment.
  • Further research and cautious development are needed for agents like IGF-1R inhibitors.
  • The efficacy of HDAC inhibitors may depend on agent selectivity.
  • Hedgehog pathway inhibitors represent a promising area for future NSCLC and SCLC therapeutic development.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.